Track 02 of 9
Hepatology & Liver Disease
NAFLD/NASH, viral hepatitis, cirrhosis and transplantation.
Hepatology in 2027 is defined by the first FDA-approved MASH therapy — resmetirom (THR-beta agonist) following MAESTRO-NASH — and the rapid expansion of GLP-1 and dual agonists (semaglutide ESSENCE, survodutide, tirzepatide) into metabolic liver disease. HCV elimination programs are being benchmarked against WHO 2030 targets, while HBV functional cure pipelines (siRNA bepirovirsen, capsid assembly modulators) advance through phase 3. The track also covers BAVENO VII portal hypertension, normothermic machine perfusion expanding the DCD donor pool, and acute-on-chronic liver failure stratification.
Focus areas
- Resmetirom and the MAESTRO-NASH biopsy endpoints
- GLP-1 and dual agonists in MASH: ESSENCE, survodutide phase 3
- HBV functional cure: bepirovirsen siRNA and capsid inhibitors
- BAVENO VII: non-selective beta-blockers and CARENA data
- Normothermic and hypothermic machine perfusion in DCD livers
- HCC surveillance and systemic therapy (atezolizumab/bevacizumab, durvalumab/tremelimumab)
- Acute-on-chronic liver failure: CLIF-C scoring and transplant timing